#Italy #Menarini #Florence #Bofanglutide #Gan & Lee

Introduction to the Partnership

In a landmark move for biopharmaceutical innovation, Gan & Lee Pharmaceuticals (stock code: 603087.SH) has entered into an exclusive licensing agreement with the Menarini Group, a multinational pharmaceutical company based in Florence, Italy. This collaboration aims to bring Bofanglutide (development code: GZR18), a promising GLP-1 receptor agonist developed by Gan & Lee, to market across Europe. The drug is currently under clinical development for treating obesity and overweight in adults, administered via subcutaneous injection once every two weeks.

Financial Valuation and Scope of Agreement

Under the terms of the agreement, Gan & Lee is set to receive an initial payment of €62 million, along with potential milestone payments that could total €664 million. Additionally, Gan & Lee will benefit from a tiered royalty structure based on net revenue generated in its licensed territories, with the overall value of the deal potentially reaching €726 million, excluding royalties.

Menarini will take the lead on the regulatory processes and marketing efforts throughout 39 countries, which include all 27 EU member states, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and several Balkan countries. This agreement represents a strategic milestone for Menarini, enhancing its focus on metabolic disorders—an increasingly prevalent issue that affects a growing population in need of effective treatments.

Product Overview: Bofanglutide

Bofanglutide is a novel experimental medication that distinguishes itself with a dosing schedule that requires an injection every two weeks, significantly reducing the frequency compared to current weekly alternatives. Previous pivotal Phase III trials conducted in China, along with Phase II studies in the United States, have shown that Bofanglutide meets its primary efficacy endpoints in weight management for adults grappling with obesity or overweight issues, demonstrating a favorable tolerability profile akin to other GLP-1 receptor agonist treatments.

Gan & Lee views Bofanglutide as a flagship product within its innovative project portfolio. With Menarini as a strategic partner, the aim is to leverage its robust presence in highly regulated markets to accelerate the global development of this pivotal asset. Moving forward, Gan & Lee aims to swiftly execute an extensive Phase III global clinical development program to obtain regulatory approval in Europe and beyond.

Leadership Comments

The partnership's potential was highlighted by Dr. Wei Chen, CEO of Gan & Lee, who remarked, "This collaboration paves the way for Bofanglutide's entry into the European market, marking a significant shift for Gan & Lee from a leader in insulins to an innovative global player in the metabolic disease arena. By combining Gan & Lee's clinical development expertise with Menarini's regulatory strategies, we aspire to offer an alternative treatment for millions suffering from obesity and overweight issues across our targeted territories."

Elcin Barker Ergun, CEO of Menarini Group, expressed enthusiasm for the collaboration: "The clinical trial outcomes thus far have demonstrated weight loss, secondary metabolic benefits, and a safety profile consistent with expectations for this medication class. The bi-weekly dosing schedule provides a distinct competitive advantage. We look forward to working closely with Gan & Lee to conduct further pivotal studies and provide this promising therapeutic option to patients across our regions."

Strategic Implications

This agreement signifies a crucial step for both companies on the global stage. For Gan & Lee, it opens the door to broader geographic expansion for its innovative projects. For Menarini, this partnership enhances its mission to deepen its footprint in the field of metabolic disorders while accelerating innovation in both primary and specialty care.

Ultimately, this licensing deal is a pivotal component of Gan & Lee’s global strategy. With Menarini's extensive market knowledge and established sales networks across Europe, the two companies are poised to efficiently advance this innovative clinical product and expand access for patients in need.

About Bofanglutide

Bofanglutide (GZR18) is an experimental GLP-1 receptor agonist poised for clinical trials that aim to address weight management in adults with obesity or overweight conditions, diabetes Type 2 (DT2), and other metabolic disorders. Presently, it is undergoing clinical investigations with a bi-weekly administration regimen. Its safety and efficacy are yet to be confirmed, and it has not received approval from the European Medicines Agency (EMA) or other health authorities.

About Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company, pioneering the industrial manufacturing of recombinant insulin analogs in China. The company has established a comprehensive R&D program for biological products and aims to comprehensively tackle treatments for diabetes and obesity while bolstering its competitive position in this therapeutic area.

About Menarini Group

Headquartered in Florence, the Menarini Group is operational in 140 countries globally, boasting consolidated revenues of $4.88 billion and a workforce of over 17,000 employees. Their extensive product portfolio spans several therapeutic areas, including cardiometabolism, oncology, gastroenterology, diabetes care, and anti-inflammatory treatments. Menarini's commitment to high-quality manufacturing and R&D continuously contributes to enhancing patient health worldwide, adhering to the highest quality standards.